Disa vaccines for Bluetongue: A novel vaccine approach for insect-borne diseases

Authors: VAN RIJN, PIET - University Of Wageningen; BOONSTRA, JAN - University Of Wageningen; DAUS, FRANZ - University Of Wageningen; FEENSTRA, FEMKE - University Of Wageningen; VAN GENNIP, RENE G.P. - University Of Wageningen; MARIS-VELDHUIS, MIEKE - University Of Wageningen; TACKEN, MIRRIAM G.J. - University Of Wageningen; VAN DE WATER, SANDRA G.P. - University Of Wageningen; POTGIETER, CHRISTIAAN - Enza Zaden; Drolet, Barbara

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 8/7/2017
Publication Date: 9/19/2017
Citation: Van Rijn, P.A., Boonstra, J., Daus, F.J., Feenstra, F., Van Gennip, R., Maris-Veldhuis, M.A., Tacken, M., Van De Water, S., Potgieter, C., Drolet, B.S. 2017. DISA vaccines for Bluetongue: A Novel Vaccine Approach for Insect-Borne Diseases. Meeting Abstract. 1/1.

Interpretive Summary:

Technical Abstract: Bluetongue virus (BTV) lacking functional NS3/NS3a protein is named Disabled Infectious Single Animal (DISA) vaccine. The BT DISA vaccine platform is broadly applied by exchange of serotype specific proteins. BT DISA vaccines are produced in standard cell lines in established production facilities, and are not pathogenic nor virulent. BT DISA vaccination induces rapid, long lasting, and serotype specific protection. BT DISA vaccination only requires a low vaccine dose, and is flexible with regard to the route of vaccination.BT DISA vaccines are virologically and serologically DIVA compatible. BT DISA vaccines are not transmitted by lack of viremia in the host and by lack of propagation in the insect vector (DISA principle).